AFP — AFT Pharmaceuticals Income Statement
0.000.00%
- AU$259.21m
- AU$276.24m
- NZ$208.02m
- 87
- 35
- 39
- 55
Annual income statement for AFT Pharmaceuticals, fiscal year end - March 31st, NZD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 113 | 130 | 157 | 195 | 208 |
Cost of Revenue | |||||
Gross Profit | 48.7 | 61.8 | 73 | 88.3 | 91.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 102 | 110 | 137 | 171 | 190 |
Operating Profit | 10.7 | 20.4 | 19.7 | 24.2 | 17.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7.89 | 18.7 | 15.8 | 22 | 16 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7.78 | 19.8 | 10.7 | 15.6 | 11.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 7.78 | 19.8 | 10.7 | 15.6 | 12 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7.59 | 19.8 | 10.7 | 15.6 | 12 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.074 | 0.19 | 0.102 | 0.149 | 0.114 |
Dividends per Share |